Godrej Agrovet Limited has formally responded to the Bombay Stock Exchange (BSE) regarding an inquiry about significant increase in trading volume of its securities across exchanges.

BSE Inquiry and Company Response

The BSE had raised a query on February 3, 2026, seeking clarification about the notable surge in trading volumes of Godrej Agrovet's shares. In response, the company issued a comprehensive statement addressing the exchange's concerns.

Compliance Confirmation

The company emphasized its commitment to transparency and regulatory compliance. Godrej Agrovet confirmed that it maintains strict adherence to disclosure requirements under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Key compliance confirmations include:

• Full compliance with SEBI listing regulations
• No undisclosed developments requiring mandatory disclosure
• Adherence to insider trading regulations
• Prompt dissemination of price-sensitive information

Management Statement

Vivek Raizada, Head – Legal & Company Secretary & Compliance Officer, signed the response on behalf of the company. The statement reaffirmed the company's position as a responsible corporate citizen committed to fulfilling all regulatory obligations.

The company assured that it would continue to make appropriate disclosures as mandated under applicable regulations whenever required, maintaining its track record of transparent communication with stakeholders and regulatory authorities.

Godrej Agrovet Limited has formally notified stock exchanges about an upcoming conference call with investors and analysts to discuss its Q3FY26 and 9MFY26 financial results. The company filed the intimation with BSE Limited and National Stock Exchange of India Limited on January 16, 2026.

Conference Call Details

The earnings call is scheduled for Wednesday, February 4, 2026, at 3:30 PM IST. Equirus Securities will host the conference call on behalf of Godrej Agrovet Limited following the announcement of financial results for the quarter and nine months ended December 31, 2025.

Management Participation

The conference call will feature senior management representatives who will participate in the earnings discussion and Q&A session:

• Mr. Nadir Godrej – Chairman
• Mr. Sunil Kataria – Chief Executive Officer & Managing Director
• Mr. S. Varadaraj – Chief Financial Officer
• Mr. Burjis Godrej – Managing Director (Astec LifeSciences)
• Mr. Arijit Mukherjee – Chief Operating Officer (Astec LifeSciences)

Call Access Information

The company has provided multiple dial-in options for participants across different regions. Domestic participants can use the primary number +91 22 6280 1224 or secondary number +91 22 7115 8125.

Session Format

The conference call will commence with a brief management discussion on the Q3FY26 and 9MFY26 earnings performance. This will be followed by an interactive Question & Answer session where analysts and investors can engage directly with the management team.

Participants are encouraged to pre-register to avoid wait time. For additional information, participants can contact Siddharth Gadekar, Associate Director – Chemicals, Metals & Mining at Equirus Securities, or Shivansh Singh, Associate – Chemicals, Metals and Mining at the same firm.

The notification was signed by Vivek Raizada, Head – Legal & Company Secretary & Compliance Officer, and the information is also available on the company's website at www.godrejagrovet.com .